A Phase 1 Study of Combination Therapy With SAR405838 and Pimasertib in Patients With Advanced Cancer
Phase of Trial: Phase I
Latest Information Update: 26 Dec 2018
Price : $35 *
At a glance
- Drugs Pimasertib (Primary) ; SAR 405838 (Primary)
- Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Lung cancer; Malignant melanoma; Pancreatic cancer; Skin cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sanofi
- 26 Dec 2018 Results published in the British Journal of Cancer
- 10 Feb 2015 Planned End Date changed from 1 Oct 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov record.
- 27 Aug 2014 Planned number of patients changed from 94 to 100 as reported by ClinicalTrials.gov record.